| THIOGENESIS THERAP. CORP. |
| Kanada |
| Gesundheit |
| CA88410L1022 / A3D51F |
| Q8M (Frankfurt) |
| FRA:Q8M, ETR:Q8M, Q8M:GR |
| - |
| https://www.thiogenesis.c.. |
|
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company developing next-generation sulfur-based therapeutics known as thiols, designed to treat inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102..
>Volltext.. |
| 17.08 Mio. EUR |
| 14.93 Mio. EUR |
| - |
| -4.27 Mio. EUR |
| -4.18 Mio. EUR |
| -0.09 EUR |
| - |
| 2.14 Mio. EUR |
| -2.86 Mio. EUR |
| 2.38 |
| - |
| -62.02% |
| - |
| - |
| - |
| - |
| THIOGENESIS |
| 14.04.26 |
|